Trials / Completed
CompletedNCT01766583
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- The Lymphoma Academic Research Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292 and lenalidomide combination therapy. Subjects will be followed for disease progression and collection of second primary malignancy (SPM) events. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts of 12 patients each.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-292 + lenalidomide | CC-292 + lenalidomide |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-11-01
- Completion
- 2018-01-01
- First posted
- 2013-01-11
- Last updated
- 2018-03-07
Locations
6 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01766583. Inclusion in this directory is not an endorsement.